Registry of Etanercept Use in Patients With Rheumatoid Arthritis in Clinical Practice in Taiwan

NCT ID: NCT00888576

Last Updated: 2012-02-08

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

441 participants

Study Classification

OBSERVATIONAL

Study Start Date

2008-12-31

Study Completion Date

2011-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to develop a registry with safety and efficacy data on the use of etanercept in clinical practice in Taiwan.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Rheumatoid Arthritis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

1

Non-intervention

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Inclusion Criteria:

Main Inclusion Criteria: 1) Male or female patients aged \> 20 years; 2) Patients who have already been selected and approved under the Taiwan National Health Insurance Program to receive 24 weeks of etanercept for rheumatoid arthritis. Main

Exclusion Criteria:

Exclusion Criteria: None
Minimum Eligible Age

20 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Pfizer

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Pfizer CT.gov Call Center

Role: STUDY_DIRECTOR

Pfizer

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Pfizer Investigational Site

Changhua, Changhua County, Taiwan

Site Status

Pfizer Investigational Site

Changhua, Changhua, Taiwan

Site Status

Pfizer Investigational Site

Lukang Zhen, Changhua, Taiwan

Site Status

Pfizer Investigational Site

Dalin, Chia-Yi, Taiwan

Site Status

Pfizer Investigational Site

Putz, Chiayi, Taiwan

Site Status

Pfizer Investigational Site

Kaohsiung City, Kaohsiung, Taiwan

Site Status

Pfizer Investigational Site

Kaohsiung City, Kaohsiung, Taiwan

Site Status

Pfizer Investigational Site

Niao Sung Hsiang, Kaohsiung, Taiwan

Site Status

Pfizer Investigational Site

Keelung, Keelung, Taiwan

Site Status

Pfizer Investigational Site

Taichung, Taichung, Taiwan

Site Status

Pfizer Investigational Site

Taichung, Taichung, Taiwan

Site Status

Pfizer Investigational Site

Taipei, Taipei, Taiwan

Site Status

Pfizer Investigational Site

Taipei TOC, Taiwan, Taiwan

Site Status

Pfizer Investigational Site

Guishanli, Taoyuan, Taiwan

Site Status

Pfizer Investigational Site

Taoyuan District, Taoyuan, Taiwan

Site Status

Pfizer Investigational Site

Hualien City, , Taiwan

Site Status

Pfizer Investigational Site

Taichung, , Taiwan

Site Status

Pfizer Investigational Site

Tainan City, , Taiwan

Site Status

Pfizer Investigational Site

Taipei, , Taiwan

Site Status

Pfizer Investigational Site

Taipei, , Taiwan

Site Status

Pfizer Investigational Site

Taipei, , Taiwan

Site Status

Pfizer Investigational Site

Taipei, , Taiwan

Site Status

Pfizer Investigational Site

Taoyuan District, , Taiwan

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Taiwan

Related Links

Access external resources that provide additional context or updates about the study.

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

0881A1-4445

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Etanercept SFP in RA Patients
NCT00413452 COMPLETED PHASE3
Observational Trial With Enbrel
NCT00488475 COMPLETED